ArticleEye (London, England)2019
Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration.
Article in Eye (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Diagnostic Accuracy of the Amsler Grid Test for Detecting Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.JAMA ophthalmology · 2023Pooled it
- Evaluating Time in Range for Visual Acuity and Macular Thickness as Outcome Measures for Randomized Clinical Trials.Translational vision science & technology · 2026Article
- Prevalence and patterns of anti-angiogenic treatment discontinuation in neovascular age-related macular degeneration-insights from health claims data.Eye (London, England) · 2026Observational
- Sustainability and minimization of carbon footprint in ophthalmology: what can we change in the outpatient clinic routine?Eye (London, England) · 2025Review
- Telemedicine in ophthalmology.Wiener medizinische Wochenschrift (1946) · 2025Review
- Quantification of Metamorphopsia Using a Smartphone-Based Hyperacuity Test in Patients With Idiopathic Epiretinal Membranes: Prospective Observational Study.JMIR perioperative medicine · 2025Observational
- Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration.Eye (London, England) · 2025Review
- Artificial intelligence technology in ophthalmology public health: current applications and future directions.Frontiers in cell and developmental biology · 2025Review
- Mobile Apps and Visual Function Assessment: A Comprehensive Review of the Latest Advancements.Ophthalmology and therapy · 2025Review
- Tackling visual impairment: emerging avenues in ophthalmology.Frontiers in medicine · 2025Review
- User-Centred Design and Development of a Smartphone Application (Healthcare (Basel, Switzerland) · 2024Article
- Knowledge, attitudes, and practices of patients with age-related macular degeneration (AMD) towards Anti-VEGF treatment under one-stop intravitreal injection model.Scientific reports · 2024Article
- [Digital remote monitoring of chronic retinal conditions-A clinical future tool? : Remote monitoring of chronic retinal conditions].Die Ophthalmologie · 2024Review
- Digital Exclusion, Social Deprivation, and Clinical Outcomes of Patients Undergoing Hyperacuity Home Monitoring.Ophthalmology and therapy · 2024Article
- Remote Monitoring of Visual Function in Patients with Maculopathy: The Aphelion Study.Ophthalmology and therapy · 2024Article
- Teleophthalmology and retina: a review of current tools, pathways and services.International journal of retina and vitreous · 2023Review
- Home vision monitoring in patients with maculopathy: current and future options for digital technologies.Eye (London, England) · 2023Review
- Transforming ophthalmology in the digital century-new care models with added value for patients.Eye (London, England) · 2023Review
- System usability, user satisfaction and long-term adherence to mobile hyperacuity home monitoring-prospective follow-up study.Eye (London, England) · 2023Article
- Prospective Study Comparing Quantitative Self-Monitoring Metamorphopsia Measurement Tools in Myopic Choroidal Neovascularization (mCNV).Clinical ophthalmology (Auckland, N.Z.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the reliability and the diagnostic performance of a novel CE (European Conformity)-marked and FDA (Food and Drug Administration)-cleared dot patient self-monitoring test (Alleye, Oculocare medical Inc.) for the detection and characterization of metamorphopsia in age-related macular degeneration (AMD).
methodsThree consecutive tests were performed in 63 wet AMD, 26 dry AMD, and 19 age-matched healthy eyes. In addition, the test was performed in 34 young healthy eyes. The mean Alleye score and standard deviations (SDs) were calculated for each eye and group. We compared and tested healthy with dry and wet AMD eyes and assessed the extent to which the test discriminated between healthy subjects and patients with dry and wet AMD using the area under the receiver operating characteristic curve (AUC).
resultsThe mean (SD) Alleye score was 49.5 (16.1) in wet AMD eyes, 62.1 (22.5) in dry AMD eyes, 69.8 (10.2) in age-matched healthy eyes, and 85.3 (10.0) in young healthy subjects. Compared to age-matched healthy subjects, the AUC (95% confidence interval) to detect wet AMD was 0.845 (0.759-0.932), and 0.660 (0.520-0.799) to discriminate between dry and wet AMD. Compared to young healthy subjects, the AUC to detect dry AMD was 0.799 (0.675-0.923), and 0.969 (0.940-0.997) to detect wet AMD.
conclusionsThis is the first assessment of Alleye in clinical practice. The test is highly accurate to detect wet AMD and reasonably accurate to classify dry vs. wet AMD. Data from longitudinal monitoring and its role in the therapeutic management of AMD is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.